We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
LENALIDOMIDE SUN/LENALIDOMIDE RBX/LENALIDOMIDE RAN (Sun Pharma ANZ Pty Ltd)
Product name
LENALIDOMIDE SUN/LENALIDOMIDE RBX/LENALIDOMIDE RAN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
141 (255 working days)
Active ingredients
Lenalidomide
Registration type
New generic medicine
Indication
Multiple Myeloma (MM)
LENALIDOMIDE SUN/LENALIDOMIDE RBX/LENALIDOMIDE RAN is indicated for the treatment of multiple myeloma.
Myelodysplastic Syndromes (MDS)
LENALIDOMIDE SUN/LENALIDOMIDE RBX/LENALIDOMIDE RAN is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Mantle Cell Lymphoma (MCL)
LENALIDOMIDE SUN/LENALIDOMIDE RBX/LENALIDOMIDE RAN is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.